



Available Online at

<http://www.ijcpa.in>

July-September 2019

DOI: <http://dx.doi.org/10.21276/ijcpa>

International Journal of  
CHEMICAL AND PHARMACEUTICAL  
ANALYSIS

eISSN: 2348-0726 ; pISSN : 2395-2466

Research Article

Volume-6

Issue-4

Article ID: 0022

## METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF AMBROXOL AND CEFPODOXIME BY RP-HPLC METHOD IN BULK AND PHARMACEUTICAL DOSAGE FORM

M Navaneetha<sup>\*1</sup>, Paul Richards M<sup>2</sup>, V Kiran Kumar<sup>3</sup>, P Govardhan Reddy<sup>4</sup>

Department of Pharmaceutical Analysis and QA, Unity College of Pharmacy, Raigir (V), Bhongir (M), Yadadri Bhongir (Dt), India,

\*Corresponding Author: Email: [richie2626@gmail.com](mailto:richie2626@gmail.com)

Received: 19 July 2018 / Revised: 30 December 2018 / Accepted: 25 July 2019 / Available online 30 September 2019

### ABSTRACT

The Present work was to develop a simple, fast, accurate, precise, reproducible, reverse phase high performance liquid chromatographic method for simultaneous estimation of ambroxol and cefpodoxime in pharmaceutical tablet dosage form marketed as doxinate. Chromatographic separation was done using Inertsil ODS RP C18 column having dimension of 4.6×250mm having particle size of 5µm, with mobile phase consisting of phosphate buffer pH 3 ±0.02 pH adjusted with ortho phosphoric acid and acetonitril (50:50 %v/v), flow rate was adjusted to 1.0 ml/min and detection wavelength at 263nm. The retention times of ambroxol and cefpodoxime was found to be 2.35 and 4.80min. The Proposed method has been validated for accuracy, precision, linearity, range, and robustness were within the acceptance limit according to ICH guidelines. Linearity for ambroxol and cefpodoxime was found in range of 25 µg-150 µg and correlation coefficient was found to be 0.999 and 0.999, %RSD for method precision was found to be 0.76, 0.82 and for system precision was 0.80 and 0.71 respectively, % mean recovery for ambroxol and cefpodoxime was found to be 99.18% to 99.48%. The method was found to be robust even by change in the mobile phase ±5% and in less flow condition. The developed method can be successfully employed for the routine analysis of ambroxol and cefpodoxime in API and Pharmaceutical dosage forms.

**Keywords** – Ambroxol, Cefpodoxime, RP-HPLC, Method development, Method validation.

### 1. INTRODUCTION

Ambroxol Hcl, trans-4-[(2-amino-3, 5 dibromobenzyl) amino] cyclohexanol hydrochloride, Bronchosecretolytic and Expectorant, used to treat asthma. It is a mucolytic expectorant that inhibits the release of arachidonic acid cell membrane phospholipids it blocks nitric oxide stimulated activation of guanylate cyclase. Cefpodoxime Proxitle IUPAC name is 6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino) acetamido]-3-(methoxymethyl)-8-oxo-5-thia-1- azabicyclo 4.2.0 oct-2-ene-2-carboxylic acid belongs to oral third generation antibiotic. It is active against most gram positive and negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis and its prodrug which is absorbed and de-esterified by the intestinal mucosa and belongs to Anti bacterial with mild to moderate infections and inactivated by certain extended spectrum beta-lactamases<sup>1-5</sup>.

## **2. MATERIALS AND METHODS**

Equipment HPLC equipped with auto sampler and PDA detector and Empower 2 (Waters) Symmetry C18 (4.6 x 150 mm, 5 $\mu$ m, Make: Waters) Lab India 3000 – double beam UV-Visible spectrophotometer. All the reagents are HPLC grade.

### **2.1 Preparation of Phosphate buffer (pH-3.5), mobile phase and diluents**

Weigh 7 grams of K Di H Ortho Phosphate and make up the volume to 1000 ml to get Ph 3.5 with ortho Phosphoric acid from this take 250 ml of Buffer and add 750 ml of ACN and degas for 5 min and filter through 0.45  $\mu$  filter under vacuum filtration and use this mobile phase as diluent .

### **2.2 Preparation of the Ambroxol HCl and Cefpodoxime Proxetil Standard and Sample Solution**

#### **Standard and Sample Solution Preparation**

Accurately weigh 12 mg and 10 mg of Ambroxol HCl and cefpodoxime Proxetil (Std) and 7 ml of the diluents and make up to 10 ml from this pipette out 0.3ml and 0.6 ml and make up the solution to 10 ml. Weigh accurately 256.9 mg of sample solution of both add 70 ml of diluent and make up the solution to 100 ml from this pipette out 0.6 ml of both and make up the solution to 10 ml .

### **2.3 Analytical Method Development**

Six trails were injected into HPLC equipped with Auto Sampler and PDA detector like methanol and water then phosphate buffer pH 3.5 is adjusted to methanol and Acetonitrile with the final optimization trial is 30:70 and no impurities was detected and sharp peak was observed with less retention time.

### **2.4 Method Validation**

#### **2.4.1 System suitability studies**

Weigh accurately 12 mg and 10 mg of both the drugs and make up the volume to 10 ml pipette out 0.3ml and 0.6 ml and make up the solution with diluent prepared as above and is given below.

#### **2.4.2 Specificity**

Weigh accurately 12 mg and 10 mg of both drugs and make up the volume to 10 ml with diluents. Pipette out 0.1 ,0.2 ,0.3 ,0.4 and 0.5 ml for ambroxol and 0.2,0.4,0.6,0.8 and 1.0 ml for Cefpodoxime for five different concentrations and inject the drug into instrument and noted the peak area value and listed in Table-2

#### **2.4.3 Precision**

Weigh accurately 12 mg and 10 mg of both the standard drugs and pipette out 0.3 ml of Ambroxol and 0.6 ml of Cefpodoxime and inject to HPLC instrument for six times and note down the peak area values and listed in Table-3.

#### **2.4.4 Accuracy**

Accurately weighed 10 mg and 12 mg of Ambroxol and Cefpodoxime transferred to two separately 10 ml and volumetric flasks, 3/4<sup>th</sup> of diluents was added and sonicated for 10 minutes. Flasks were made up with diluents and labeled as Standard stock solution (1000  $\mu$ g/ml of Belinostat)

**2.4.5 Robustness**

Standard solution 36 ppm of Ambroxol HCl and 60 ppm of Cefpodoxime Proxetil was prepared and analysed using the varied flow rates along with method flow rate.


The Organic composition in the Mobile phase was varied from 70 % to 80 %. Standard solution 36 µg/ml of Ambroxol HCl and 60 µg/ml of Cefpodoxime Proxetil was prepared and analysed using the varied Mobile phase composition along with the actual mobile phase composition in the method.

**2.4.6 Limit of Detection and Quantitation**

Weigh accurately 12 mg and 10 mg of ambroxol and cefpodoxime and make up the solution with diluents to 10ml from this pipette out 0.3 ml and 0.6 ml and make up the volume to 10 ml again both 1 ml pipette out and make the solution to 10 ml gives 0.03 and 0.05 micro g/ml for limit of detection and quantitation and all the limits of S/N ratio are within the range.

**3. RESULTS AND DISCUSSION**

The selectivity of the method was revealed by the repeated injection of mobile phase and no interference was found. The recovery studies were carried out by preparing three individual samples with same procedure from the formulation and injecting. The standard drug solution of varying concentration ranging from 12-60µg / ml for Ambroxol Hcl and 20-100 µg / ml for Cefpodoxime proxitile. Both peaks are eluted clearly, more plate count and more resolution was observed.



**Fig 1: Representative chromatogram of standard**

**Table 1: System Suitability Parameters of AMB and CEF.**

| Sl. No | Parameters               | Cefpodoxime | Ambroxol |
|--------|--------------------------|-------------|----------|
| 1      | System Suitability       | 6.3         | 6.3      |
| 2      | Tailing factor           | 1.2         | 1.2      |
| 3      | No of theoretical plates | 3744        | 4750     |
| 4      | Retention time           | 3.304       | 2.162    |

**Table 2: Linearity Parameters of AMB and CEF**

| Sl. No | Linearity level | Concentration | Peak area AMB | Peak area CEF |
|--------|-----------------|---------------|---------------|---------------|
| 1      | I               | 12ppm         | 374052        | 545062        |
| 2      | II              | 24ppm         | 682802        | 1052605       |
| 3      | III             | 36ppm         | 1012619       | 1515308       |
| 4      | IV              | 48ppm         | 1324938       | 2050501       |
| 5      | V               | 60ppm         | 1708316       | 2635141       |

**Table 3: Precision Parameters of AMB and CEF.**

| Injection   | AMB     | CEF     |
|-------------|---------|---------|
| Injection-1 | 1015722 | 1496209 |
| Injection-2 | 1016087 | 1507963 |
| Injection-3 | 1018135 | 1521163 |
| Injection-4 | 1019549 | 1522810 |
| Injection-5 | 1032335 | 1528916 |
| Injection-6 | 1020365 | 1515412 |

**Table 4: Accuracy Parameters of AMB and CEF**

| Concentration | Area     |          | Amount added |     | Amount Found |      | % Recovery |      | Mean Recovery |
|---------------|----------|----------|--------------|-----|--------------|------|------------|------|---------------|
|               | AMB      | CEF      | AMB          | CEF | AMB          | CEF  | AMB        | CEF  |               |
| 50%           | 605652.5 | 774787.7 | 6            | 5   | 5.8          | 5    | 98.1       | 101  | 99.5          |
| 100%          | 1246314  | 1537580  | 12           | 10  | 12.1         | 10.0 | 101.0      | 100  | 100           |
| 150%          | 1869868  | 2285575  | 18           | 15  | 18.1         | 14.9 | 101.0      | 99.4 | 99.5          |

**Table 5: Robustness Parameters of AMB and CEF**

| Sl. no | Flow rate (ml/min) | Ambroxol        |         | Cefpodoxime     |         |
|--------|--------------------|-----------------|---------|-----------------|---------|
|        |                    | USP Plate count | Tailing | USP Plate count | Tailing |
| 1      | 0.8                | 4479            | 1.3     | 3086            | 1.1     |
| 2      | 1.0                | 4750            | 1.2     | 3744            | 1.2     |
| 3      | 1.2                | 4099            | 1.2     | 3072            | 1.1     |

**4. CONCLUSION**

Where the RP-HPLC method in which determination of Cefpodoxime proxetil and Ambroxol HCl was carried out on a Symmetry C18 (4.6 x 150mm, 5µm, Make: Waters) using a mobile phase consisting of pH 3.5 phosphate buffer : Acetonitrile (30:70). The mobile phase was pumped at a rate of 1.0 ml/min and the detection was carried out at 254nm. The retention time of Cefpodoxime proxetil and Ambroxol HCl was found to be 2.162 and 3.305 min.

**5. ACKNOWLEDGEMENT**

Author sincerely thanks to the Chandra Labs Hyderabad for providing the pure drug for carry out my work and thank the Unity College of Pharmacy management for their continuous support and encouragement for my research work.

**REFERENCES**

1. Abirami G, Vetrichelv T. Development, and validation of RP-HPLC method for the determination of cefpodoxime proxetil and ambroxol hydrochloride in pharmaceutical formulation. IJPT. 2013;4(4):5028-37.
2. Kotkar RP, Shirkhedkar AA, Surana J. Development and Validation of RP-HPLC method for simultaneous estimation of Cefpodoxime Proxetil and Ambroxol Hydrochloride in bulk and in tablets. International Journal of Research in Pharmaceutical and Biomedical Sciences. 2012; 3:156-9.
3. Patel SM, Mehta MR, Dave JB, Patel CN. The RP-HPLC Method for Simultaneous Estimation of Cefpodoxime Proxetil and Ambroxol Hydrochloride in their Combined tablet dosage formulation. Inventi Rapid: Pharm Ana and Qual Assur. 2012 Jun 12.
4. Nagappan KV, Meyyanathan SN, Raja RB, Reddy S, Jeyaprakash MR. Development of RP-HPLC method for simultaneous estimation of Ambroxol hydrochloride and Loratidine in pharmaceutical formulation. Res J Pharm Tech 2008;1(4):366-9.
5. Kim H, Yoo JY, Han SB, Lee HJ, Lee KR. Determination of ambroxol in human plasma using LC-MS/MS. J Pharm Biomed Anal 2003;32:209-16.